InvestorsHub Logo
Followers 17
Posts 752
Boards Moderated 0
Alias Born 10/20/2013

Re: None

Saturday, 10/29/2016 9:18:15 AM

Saturday, October 29, 2016 9:18:15 AM

Post# of 733
A lot of chatter on other boards about a possible taker over offer or an imminent partnership deal.

I truly don't hope an acquisition will materialize. $10-15 right now would be a disappointment.

A partnership deal would make sense and be beneficial. FDA approval for EPP seems like a shoe in and after the pre-NDA meeting in November the Vitiligo program should get more attention. Clinuvel has stated numerous times that the EPP and Vitiligo programs are intertwined in the US, most likely meaning that a majority of the data package with regard to safety etc. will be the groundwork in a forthcoming NDA for Vitiligo. Therefore, the submission of an NDA for EPP at a stage where everyone anticipates the FDA to approve also constitutes a good opportunity for a partner to come in and take the lead on Vitiligo.

The chairman has been touting an enlargement of the "group" lately and I believe that a such is imminent. The question is which form it will take.

The recent rise in share price is nice but does in no way reflect the true value of this company. A buyout would be tragic. A partner would be welcomed.